Combined treatment with a β-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice

Bone

Volumn 39, Issue 2, 2006, Pages 260-267

  Pierroz, Dominique D ^a   Bouxsein, Mary L ^b   Rizzoli, René ^a   Ferrari, Serge L ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

blocker; Bone; Mouse; Ovariectomy; PTH

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; OSTEOCALCIN; PARATHYROID HORMONE; PROPRANOLOL;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE REMODELING; CANCELLOUS BONE; CORTICAL BONE; DRUG EFFECT; DRUG RESPONSE; ESTROGEN DEFICIENCY; FEMUR; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE; SPINE; TRABECULAR BONE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BONE AND BONES; BONE DENSITY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FEMUR; MICE; MICE, INBRED C57BL; OVARIECTOMY; PARATHYROID HORMONE; PROPRANOLOL; RANDOM ALLOCATION; TIME FACTORS;

EID: 33744904181     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.01.145     Document Type: Article

References (43)

1. Alexander J.M., Bab I., Fish S., Muller R., Uchiyama T., Gronowicz G., et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J. Bone Miner. Res. 16 (2001) 1665-1673
2. Andersson N., Lindberg M.K., Ohlsson C., Andersson K., and Ryberg B. Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice. J. Endocrinol. 170 (2001) 529-537
3. Arai M., Nagasawa T., Koshihara Y., Yamamoto S., and Togari A. Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim. Biophys. Acta 1640 (2003) 137-142
4. Baumann B.D., and Wronski T.J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16 (1995) 247-253
5. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
6. Bouxsein M.L., Pierroz D.D., Glatt V., Goddard D.S., Cavat F., Rizzoli R., et al. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bone Miner. Res. 20 (2005) 635-643
7. Chappard D., Retailleau-Gaborit N., Legrand E., Basle M.F., and Audran M. Comparison insight bone measurements by histomorphometry and microCT. J. Bone Miner. Res. 20 (2005) 1177-1184
8. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16 (2001) 925-931
9. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16 (2001) 1846-1853
10. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 (2005) 514-520
11. Ferrari S.L., Pierroz D.D., Glatt V., Goddard D.S., Bianchi E.N., Lin F.T., et al. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. Endocrinology 146 (2005) 1854-1862
12. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
13. Herskovits M.S., and Singh I.J. Effect of guanethidine-induced sympathectomy on osteoblastic activity in the rat femur evaluated by 3H-proline autoradiography. Acta. Anat. (Basel) 120 (1984) 151-155
14. Hildebrand T., Laib A., Muller R., Dequeker J., and Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J. Bone Miner. Res. 14 (1999) 1167-1174
15. Hildebrand T., and Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput. Methods Biomech. Biomed. Eng. 1 (1997) 15-23
16. Hill E.L., and Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264 (1991) 469-480
17. Hirano T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14 (1999) 536-545
18. Hohmann E.L., Elde R.P., Rysavy J.A., Einzig S., and Gebhard R.L. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 232 (1986) 868-871
19. Iida-Klein A., Lu S.S., Yokoyama K., Dempster D.W., Nieves J.W., and Lindsay R. Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J. Clin. Densitom. 6 (2003) 25-33
20. Iida-Klein A., Zhou H., Lu S.S., Levine L.R., Ducayen-Knowles M., Dempster D.W., et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J. Bone Miner. Res. 17 (2002) 808-816
21. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18 (2003) 1932-1941
22. Khosla S. Parathyroid hormone plus alendronate-A combination that does not add up. N. Engl. J. Med. 349 (2003) 1277-1279
23. Kneissel M., Boyde A., and Gasser J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28 (2001) 237-250
24. Kostenuik P.J., Capparelli C., Morony S., Adamu S., Shimamoto G., Shen V., et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142 (2001) 4295-4304
25. Leung C.K., and Lam F.K. Performance analysis for a class of iterative image thresholding algorithms. Pattern Recogn. 29 (1996) 1523-1530
26. Minkowitz B., Boskey A.L., Lane J.M., Pearlman H.S., and Vigorita V.J. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. 9 (1991) 869-875
27. Mohan S., Kutilek S., Zhang C., Shen H.G., Kodama Y., Srivastava A.K., et al. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 27 (2000) 471-478
28. Moore R.E., Smith II C.K., Bailey C.S., Voelkel E.F., and Tashjian Jr. A.H. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 23 (1993) 301-315
29. Mosekilde L., Jastrup B., Melsen F., Lund B., Sorensen O.H., Nielsen H.E., et al. Effect of propranolol treatment on bone mass, bone mineral content, bone remodelling, parathyroid function and vitamin D metabolism in hyperthyroidism. Eur. J. Clin. Invest. 14 (1984) 96-102
30. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
31. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
32. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., and Nicholson G.C. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. 19 (2004) 19-24
33. Reid I.R., Gamble G.D., Grey A.B., Black D.M., Ensrud K.E., Browner W.S., et al. beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 20 (2005) 613-618
34. Reid I.R., Lucas J., Wattie D., Horne A., Bolland M., Gamble G.D., et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab. 90 (2005) 5212-5216
35. Ridler T., and Calvard S. Picture thresholding using an iterative selection method. IEEE Trans Syst. Man Cybern. SMC-8 (1978) 630-632
36. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2005) 177-184
37. Schlienger R.G., Kraenzlin M.E., Jick S.S., and Meier C.R. Use of beta-blockers and risk of fractures. JAMA 292 (2004) 1326-1332
38. Shen V., Dempster D.W., Mellish R.W., Birchman R., Horbert W., and Lindsay R. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif. Tissue Int. 50 (1992) 214-220
39. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
40. Takeuchi T., Tsuboi T., Arai M., and Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol. 61 (2001) 579-586
41. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc. Res. Tech. 58 (2002) 77-84
42. Togari A., Arai M., Mizutani S., Koshihara Y., and Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 233 (1997) 125-128
43. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520